Literature DB >> 24334069

Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta.

Peter S Freestone1, Ezia Guatteo2, Fabiana Piscitelli3, Vincenzo di Marzo3, Janusz Lipski4, Nicola B Mercuri5.   

Abstract

Endocannabinoids (eCBs) modulate synaptic transmission in the brain, but little is known of their regulatory role in nigral dopaminergic neurons, and whether transmission to these neurons is tonically inhibited by eCBs as seen in some other brain regions. Using whole-cell recording in midbrain slices, we observed potentiation of evoked IPSCs (eIPSCs) in these neurons after blocking CB1 receptors with rimonabant or LY-320,135, indicating the presence of an eCB tone reducing inhibitory synaptic transmission. Increased postsynaptic calcium buffering and block of mGluR1 or postsynaptic G-protein coupled receptors prevented this potentiation. Increasing spillover of endogenous glutamate by inhibiting uptake attenuated eIPSC amplitude, while enhancing the potentiation by rimonabant. Group I mGluR activation transiently inhibited eIPSCs, which could be prevented by GDP-β-S, increased calcium buffering or rimonabant. We explored the possibility that the dopamine-derived eCB N-arachidonoyl dopamine (NADA) is involved. The eCB tone was abolished by preventing dopamine synthesis, and enhanced by l-DOPA. It was not detected in adjacent non-dopaminergic neurons. Preventing 2-AG synthesis did not affect the tone, while inhibition of NADA production abolished it. Quantification of ventral midbrain NADA suggested a basal level that increased following prolonged depolarization or mGluR activation. Since block of the tone was not always accompanied by attenuation of depolarization-induced suppression of inhibition (DSI) and vice versa, our results indicate DSI and the eCB tone are mediated by distinct eCBs. This study provides evidence that dopamine modulates the activity of SNc neurons not only by conventional dopamine receptors, but also by CB1 receptors, potentially via NADA.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cannabinoids; Dopaminergic; Electrophysiology; Parkinson's disease; Synaptic transmission

Mesh:

Substances:

Year:  2013        PMID: 24334069     DOI: 10.1016/j.neuropharm.2013.12.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.

Authors:  William J Redmond; Erin E Cawston; Natasha L Grimsey; Jordyn Stuart; Amelia R Edington; Michelle Glass; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-11-17       Impact factor: 8.739

Review 2.  Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Mol Neurodegener       Date:  2015-04-08       Impact factor: 14.195

Review 3.  N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.

Authors:  Urszula Grabiec; Faramarz Dehghani
Journal:  Cannabis Cannabinoid Res       Date:  2017-07-01

Review 4.  The Role of Lipids in Parkinson's Disease.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Cells       Date:  2019-01-07       Impact factor: 6.600

5.  Adolescent Exposure to WIN 55212-2 Render the Nigrostriatal Dopaminergic Pathway Activated During Adulthood.

Authors:  Enzo Javier Pérez-Valenzuela; María Estela Andrés Coke; Anthony A Grace; José Antonio Fuentealba Evans
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.